Large-scale genetic association studies have identified replicable susceptibility alleles for some psychiatric phenotypes. This includes both common and rare variants. A striking finding has been that susceptibility variants identified to date often confer susceptibility to more than one of the traditional clinical phenotypes, a finding that has the potential to increase understanding of the biological relationship between these traditional diagnostic categories. The focus of this study is childhood attention-deficit hyperactivity disorder (ADHD) and its potential genetic relationship to adult schizophrenia and bipolar disorder. There is recent evidence of some degree of shared genetic susceptibility between schizophrenia and childhood ADHD for rare chromosomal variants. In the present study, we have considered another possible source of genetic overlap, namely common single nucleotide polymorphisms (SNPs) and we have extended the analysis to consider bipolar disorder as well as schizophrenia. The only prior study that has started to examine this, selected six bipolar genetic risk variants and identified no strong association with ADHD or with scores on the Mood Disorder Questionnaire. Here, we have used a more powerful, genome-wide approach and examined whether, when they are considered en masse using polygenic score analysis, multiple schizophrenia and bipolar disorder common risk alleles contribute to ADHD risk.

In general, we followed the polygenic score analysis approach described by the International Schizophrenia Consortium (ISC). The basic principle of that analysis was that a set of many alleles that discriminated case status in a ‘discovery’ schizophrenia case–control sample, also significantly discriminated case status in an independent ‘target’ schizophrenia case–control sample. We used the published Psychiatric Genome-wide Association Study (GWAS) Consortium (PGC) data-sets (schizophrenia and bipolar disorder) as two separate discovery sets and our ADHD data as the target set.

**Method**

We used recently published Psychiatric Genome-wide Association Study (GWAS) Consortium (PGC) adult schizophrenia data to define alleles over-represented in people with schizophrenia and tested whether those alleles were more common in 727 children with ADHD than in 2067 controls.

**Results**

Schizophrenia risk alleles discriminated ADHD cases from controls ($P = 1.04 \times 10^{-6}$, $R^2 = 0.45$); stronger discrimination was given by alleles that were risk alleles for both adult schizophrenia and adult bipolar disorder (also derived from a PGC data-set) ($P = 9.98 \times 10^{-6}$, $R^2 = 0.59$).

**Conclusions**

This increasing evidence for a small, but significant, shared genetic susceptibility between adult schizophrenia and childhood ADHD highlights the importance of research work across traditional diagnostic boundaries.

**Declaration of interest**

None.

**Sample**

Discovery data

We made use of the PGC schizophrenia and bipolar disorder case–control data-sets. The schizophrenia sample comprised 9394 cases and 12 462 controls analysed at 1 252 901 SNPs. The bipolar disorder sample comprised 7481 cases and 9250 controls analysed at 2 427 089 SNPs. These studies contain individuals of European origin collected across Europe, the USA, and Australia. We note that there are a number of control individuals that contribute to both the PGC schizophrenia and bipolar disorder samples, including the Wellcome Trust Case Control Consortium (WTCCC) – Phase 1 control sample.

Target data

We interrogated genotype data from a UK/Irish ADHD GWAS. The sample comprises 727 children aged 4–18 years, recruited from UK community child psychiatry and paediatric clinics and from Dublin, Ireland. All children were White, of European origin and met research diagnostic criteria for DSM-III-R/DSM-IV or ICD-10 for ADHD or hyperkinetic disorder. Case exclusion criteria included bipolar disorder, schizophrenia, autism, epilepsy, intellectual disability (IQ < 70) or any known major neurological or medical disorders. After complete description of the study to the participants, written informed consent was obtained. The ADHD GWAS sample also included 5081 UK controls from WTCCC2. Genotyping for the ADHD cases was performed on the Illumina (San Diego, California, USA, www.illumina.com) Human 660W-Quad BeadChip, and genotyping for the controls

---

1See editorial, pp. 81–83, this issue.
was performed using the Illumina Human 1.2M BeadChip. The samples, quality control assessment and results of the primary ADHD GWAS are described in detail in a previous paper.10

Statistical analysis

Approximately half of the WTCCC2 control sample had been used in the primary bipolar disorder GWAS reported by WTCCC19 and a schizophrenia GWAS reported by our own group,15 both of which contributed to the PGC studies of bipolar disorder and schizophrenia respectively. It was, therefore, necessary to remove those and any overlapping case individuals from our ADHD GWAS. First, we identified individuals that were included in the earlier studies (genotyped on Affymetrix GeneChip 500K Mapping Array; Santa Clara, California, USA, www.affymetrix.com) that were also present in the primary ADHD GWAS. To do this we used 71 565 SNPs that were common to the studies that had also passed our quality control procedures. These SNPs were used to estimate identity-by-descent statistics for all pair-wise combinations of individuals. Across the two data-sets, we identified 2474 related individuals in the control sample, of which 2452 were duplicates, and no related case individuals. The related controls comprised 13 parent–offspring pairs, 7 sibling pairs, and 2 half-sibling or avuncular pairs. The duplicates and close relatives were removed from the control set giving a sample of 2067 control and 727 case individuals for our analysis of ADHD cases v. controls. Similar quality control approaches have been applied to our ADHD,10 bipolar disorder9 and schizophrenia15 case and control samples to exclude overlapping and related individuals. Given that we have previously provided the results of the full ADHD GWAS elsewhere,10 we do not provide individual-level SNP results here.

We interrogated the data further by creating polygenic scores based on simultaneous patterns of association in the PGC schizophrenia and bipolar disorder data-sets. Specifically, we were interested in testing the hypothesis that the set of alleles that showed evidence for association in both schizophrenia and bipolar disorder was the same set of alleles that was enriched for shared effects in ADHD risk. Alternative (non-null) hypotheses are that alleles that were relatively specific for one or the other disorder were enriched for those that confer risk of ADHD.

Table 1: Summary of results in the target sample comparing ADHD cases v. controls

<table>
<thead>
<tr>
<th>Discovery sample</th>
<th>SNP selection criteria</th>
<th>SNPs, n</th>
<th>z-statistic</th>
<th>R², %</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bipolar disorder</td>
<td>Bipolar disorder (P&lt;0.5)</td>
<td>50512</td>
<td>1.94</td>
<td>0.11</td>
<td>0.0519</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Schizophrenia (P&lt;0.5)</td>
<td>48494</td>
<td>3.88</td>
<td>0.45</td>
<td>1.04 × 10⁻⁴</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Schizophrenia (P&lt;0.5) and bipolar disorder (P&gt;0.5)</td>
<td>22595</td>
<td>1.63</td>
<td>0.080</td>
<td>0.102</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Schizophrenia (P&lt;0.5) and bipolar disorder (P&lt;0.5)</td>
<td>25137</td>
<td>4.40</td>
<td>0.58</td>
<td>1.09 × 10⁻⁵</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Same direction of effect in schizophrenia and bipolar disorder</td>
<td>17303</td>
<td>4.42</td>
<td>0.59</td>
<td>9.98 × 10⁻⁶</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Different direction of effect in schizophrenia and bipolar disorder</td>
<td>7834</td>
<td>1.21</td>
<td>0.044</td>
<td>0.225</td>
</tr>
</tbody>
</table>

ADHD, attention-deficit hyperactivity disorder; SNP, single nucleotide polymorphism.

Results

The polygenic score representing schizophrenia risk was significantly different between ADHD cases and controls, with higher scores observed in the ADHD cases (Table 1). Attention-deficit hyperactivity disorder cases also had a higher polygenic score representing...
bipolar disorder risk but the effect was weaker than that for the polygenic score representing schizophrenia as estimated by $R^2$, and just failed to attain a conventional level of statistical significance. For both analyses, the magnitudes of these effects (as defined by $R^2$) were much smaller than the 6% or 3% observed when the discovery and target sets both comprise schizophrenia2 or both bipolar disorder8 data-sets respectively.

In the analyses based on the patterns of association in schizophrenia conditional on that in bipolar disorder, only the set of SNPs that surpassed $P_{i} < 0.5$ in both samples produced a significant score difference between ADHD cases and controls ($P = 1.09 \times 10^{-5}$). This effect appeared to be largely driven by the set of alleles with the same direction of effect in schizophrenia and bipolar disorder ($P = 9.98 \times 10^{-8}$). The scores derived from the set in which the alleles had opposite effects in schizophrenia than in bipolar disorder were not significantly different between ADHD cases and controls. Findings that were significant in Table 1 (plus the bipolar disorder analysis) are presented in online Fig. DS2 for a range of different significance thresholds. Consistent with the findings of the ISC, $P<0.5$ gives most evidence for discrimination of ADHD cases from controls. Our significant results are maintained across the full range of thresholds.

For polygenic score analysis, the number of alleles used in the analysis can have a large effect on significance and the effect size estimated from $R^2$. The number of alleles differed substantially between those that were in the same direction in schizophrenia and bipolar disorder ($n = 17\,303$) and those that were in opposite directions ($n = 7\,834$). We, therefore, undertook a simulation study to assess the impact of this variable on our evaluation of the contribution from alleles at SNPs surpassing $P_{i} < 0.5$ but for which the direction of association differed in schizophrenia and bipolar disorder. From the 25\,137 SNPs surpassing $P_{i} < 0.5$ in both disorders (i.e. schizophrenia and bipolar disorder), we selected at random a subset of 7\,834 SNPs (i.e. the number that had been included in the analysis of SNPs showing different directions of effect), and the remaining subset of 17\,303 SNPs (i.e. the number that had been included in the analysis of SNPs showing the same direction of effect), and performed polygenic score analysis on both sets of SNPs. The difference in $R^2$ was estimated from the two analyses. Repeating the procedure 10,000 times gave a distribution of difference in $R^2$ against which we could empirically evaluate whether our observation of a weaker result for the SNPs with opposite directions of effect simply reflects a smaller set of SNPs being used. In the simulated data, the probability of observing a difference in $R^2$ at least as large as that observed in the real data (i.e. observed difference in $R^2 = 0.55$) was 0.09 (i.e. in 900 out of 10,000 random SNP draws was a larger difference in $R^2$ detected than in the observed data). This does not allow us to reject the null hypothesis that there is no difference in the SNPs associated with schizophrenia and bipolar disorder at $P<0.5$ with respect to the direction of effect. This in turn amounts to suggestive evidence ($P = 0.09$) that alleles that are over-represented in the cases in both schizophrenia and bipolar disorder GWAS data-sets proportionately capture more polygenic signal than those alleles that are more common in schizophrenia, but less common in bipolar disorder, when compared with controls.

**Discussion**

Aetiological overlaps between childhood-onset and major adult psychiatric disorders have, until relatively recently, been ignored in molecular genetic studies. Here, using a sample of 727 children and adolescents affected with ADHD and 2607 controls, we have demonstrated significant evidence for an overlap in polygenic susceptibility to schizophrenia and ADHD. No significant evidence was observed for a similar overlap between polygenic susceptibility to bipolar disorder and ADHD, although the level of significance was suggestive, so a potential relationship may be detectable in future studies with larger samples. This is the first study of its kind to identify a SNP-based relationship between ADHD risk and that for either schizophrenia or bipolar disorder. In this study, the overlap between ADHD and schizophrenia appears stronger than it is between ADHD and bipolar disorder. However, this could, in part, be related to somewhat lower power (i.e. smaller sample size) of the PGC bipolar disorder sample than the PGC schizophrenia samples used in the discovery part of the analysis, although the differences in sample size are not marked. The estimated effect sizes of the schizophrenia and bipolar disorder polygenic risk scores we report here in our ADHD sample are smaller than those observed by the ISC when taking schizophrenia-defined score alleles and investigating these in individuals with schizophrenia or bipolar disorder compared with controls (2–3% and 1–2% respectively). The estimated effect sizes for bipolar disorder-defined score alleles in our ADHD v. control analysis are smaller than that observed when we reanalyse our data using the ISC schizophrenia data-set as discovery data (see the online supplement). As the ISC sample size (about 7000 individuals in total) is smaller than that of either the PGC schizophrenia or bipolar disorder sample, the discovery sample size cannot be a major factor driving the lower effect sizes seen here.

An observation that may help to provide insight into the genetic architecture of the relationship between the various disorders is the larger effect, as measured by $R^2$ for sets of SNPs that show similar directions of effect in schizophrenia and bipolar disorder. This observation needs to be treated with some caution because of the occurrence of some shared controls within the PGC schizophrenia and bipolar disorder data-sets that biases towards finding more shared susceptibility alleles than would be expected under the null hypothesis. Nonetheless, if this observation receives support in independent studies, it would suggest that not all schizophrenia susceptibility alleles are equivalent. They may reflect different phenotypic risk effects. Alternatively, given the overlap in schizophrenia and bipolar disorder, they may reflect the more ‘replicable’ or true alleles.

It is important to acknowledge that our findings do not distinguish between susceptibility alleles that may be (a) highly non-specific and span across multiple psychiatric conditions (not just schizophrenia and ADHD) and those that may be (b) relatively specific to schizophrenia and ADHD. Distinguishing between these possibilities will require studies that include a wider range of psychiatric phenotypes.

The links between ADHD, other early neurodevelopmental disorders (notably autism) and later-onset major psychiatric disorders are of growing interest. A subgroup of children with ADHD, but not a majority, develops later mood and bipolar affective disorder. The relationship with schizophrenia has been less well researched, although it is well recognised that a substantial proportion of those with schizophrenia and their offspring show early developmental problems that include attentional difficulties. Studies of ADHD in families in which a parent is affected with schizophrenia show that, in comparison with the offspring without ADHD, the offspring affected with ADHD experienced more neurological dysfunction,20 functional impairments,20 psychotic-like symptoms21 and an increased risk of developing schizophrenia spectrum disorders.19,22 A history of DSM-IV childhood ADHD is also found to be more frequent in patients with schizophrenia spectrum disorders and in individuals at risk of developing these disorders than in the general population, although the reported
prevalence rate of ADHD varies widely, a likely consequence of sample characteristics. Our results suggest that these observed links may in part follow from a shared genetic liability to ADHD and schizophrenia and that further investigation of whether they index specific neurodevelopmental impairments is needed.

Our observation of an overlap in genetic susceptibility for common variants in the current analysis is consistent with an observation of an overlap in genetic susceptibility between ADHD and schizophrenia for rare copy number variants (CNVs). In that study, based on a smaller sample of 366 ADHD case individuals (a subset of the sample presented here), we found that large (> 500 kb), rare CNVs were significantly more common in cases than controls, and that CNVs identified in the ADHD cases were significantly enriched for loci previously reported in both autism \( (P = 0.0095) \) and schizophrenia \( (P = 0.010) \). We note that when excluding ADHD samples known to have large CNVs, our results are unchanged. Taken together with the current results, this is supportive evidence for an overlap in common, as well as rare, risk variants for ADHD and schizophrenia. We propose that in conjunction with the CNV data, this is suggestive evidence for the genetic architecture of ADHD being closer to schizophrenia than bipolar disorder.

As mentioned in the introduction, a striking finding from GWAS of psychiatric disorders has been the overlap in genetic association signals across different psychiatric disorders. An important goal of PGC, the international consortium for analysing psychiatric GWAS data, is to undertake systematic cross-disorder analyses using data-sets for schizophrenia, bipolar disorder, recurrent depression, autism and ADHD. The vast majority of the ADHD data that we report here are not included within the Cross Disorders Group (CDG) analyses (see online supplement for details). When the PGC CDG analyses are available it will be important to explore the similarities and differences between findings in the two data-sets.

Strengths and limitations

There are several strengths of this study including the systematic genome-wide approach, the large size of the training samples and the novelty of the analysis applied to ADHD and schizophrenia. It is, however, important to consider potential limitations. As with all large-scale genotyping approaches, there is the possibility that systematic bias may influence the results. Population stratification is a confounder that can cause bias in case-control studies. We do not believe that population stratification has resulted in the findings presented here. First, we take into account principal components of our genotype data to adjust for hidden stratification. Second, the ISC excluded population stratification as an explanation for the broad effects seen between cases and controls. Finally, it is highly unlikely that exactly the same stratification differences would occur between the case and comparison data-sets in both discovery and target samples. We cannot exclude the possibility that genotyping platform has influenced our results. However, extensive quality control was performed for the PGC schizophrenia and bipolar disorder samples, and the target ADHD GWAS sample to ensure the genotypes for the case and control samples were comparable. A further potential source of bias is the theoretical possibility that by chance, or otherwise, our sample could have unusual phenotypic characteristics that increased the likelihood of a genetic similarity between ADHD and schizophrenia or bipolar disorder. Such an eventuality could, in principle, influence the statistical comparisons and/or limit the generalisability of findings to other samples. However, although noting that systematic phenotypic differences could occur, we are not aware of such select effects in our sample and have no reason to believe this affects our results or conclusions.

It is important to stress that the statistical significance seen in the comparisons we report are driven by large sample sizes, not large effect sizes. As in previous studies that use the polygenic score approach, the proportion of variance explained is negligible (<1% of the variance in the present study). However, we should note that the underlying variance being captured indirectly may be considerably greater. Indeed, in the ISC study, although \( R^2 \) was about 3%, the true total underlying variation in liability estimated by the polygenic model was approximately 33%, a conclusion broadly supported by similar analyses of the PGC data, and by an analysis of the PGC data using an entirely different approach. As an increasing proportion of the common genetic variation is accurately captured through increased sample sizes, it can be expected that much more of the variance attributable to the polygenic contributions, unique and shared across disorders, will be explained. This approach may therefore become an increasingly useful research tool for probing the relationships between disorders, and even potentially a useful clinical tool.

In summary, we provide evidence that common genetic variation contributes to risk for ADHD. ‘Risk’ alleles from schizophrenia in particular, and also bipolar disorder to some extent, are found to differentiate ADHD cases from control individuals. Our results indicate the need for further studies of the genetic relationship between ADHD and adult mood and psychotic disorders.

**Funding**

The ADHD research project was funded by the Wellcome Trust. We thank the Wellcome Trust Case Control Consortium 2 for making available the control data project funded by the Wellcome Trust (grant 083948/2/07/2). We acknowledge use of the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000994 and the Wellcome Trust grant 086425/Z/08/Z, as well as the UK Blood Services collection of Common Controls (UKBS-CC collection) funded by the Wellcome Trust grant 076113/C/04/Z and by the NIHR programme grant to NHSBT (RP-PG-0310-1002).

**Acknowledgements**

We would like to thank all the families and clinicians who participated in the ADHD research project. We also thank all those who participated in, or helped with, the bipolar disorder sample collection, including members of the Bipolar Disorder Research Network and Bipolar UK, and are indebted to the Wellcome Trust Case Control Consortium (WTCCC2) for genotyping the bipolar disorder sample. We are grateful to many colleagues within the Psychiatric GWAS Consortium (PGC) Schizophrenia Workgroup and Bipolar Disorder Workgroup for their collaborative analyses and publications that informed our current polygenic analysis.

**References**


9 Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661–78.


16 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–75.


20 Oner D, Munir K. Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. Schizophr Res 2005; 76: 293–9.


Online supplement

To investigate whether the larger estimate of effect size ($R^2$) from the schizophrenia analysis (compared with the bipolar disorder analysis) is an artefact of power from a larger discovery sample, we repeated our analysis using as discovery data the results data from the International Schizophrenia Consortium (ISC). The ISC data comprises 3322 European individuals with schizophrenia and 3587 controls, and forms part of the Psychiatric Genome-wide Association Study (GWAS) Consortium (PGC) of schizophrenia, and is therefore a less powerful discovery sample than the full PGC study. The number of single nucleotide polymorphisms (SNPs) that overlapped with our attention-deficit hyperactivity disorder (ADHD) study was much reduced, so for direct comparison with results from the PGC schizophrenia data, a set of SNPs was identified that were present in both the PGC study of schizophrenia and the ISC. Results are shown in Table DS1 and, along with the results in Table 1, indicate that (1) the inclusion of more SNPs in the analysis provides for a more significant analysis of the data, and (2) the inclusion of larger discovery samples increase the power for detecting a difference between ADHD and controls. We also found that using the ISC data as the discovery sample (fewer individuals and SNPs), larger estimates of $R^2$ were obtained than that found when employing the PGC study of bipolar disorder as the discovery sample. Therefore the discovery sample size is not a major factor driving the lower effect sizes seen here with bipolar disorder score alleles.
**Table DS1** Summary of results in the target sample, comparing ADHD cases v. controls for a smaller set of SNPs available also in the ISC sample

<table>
<thead>
<tr>
<th>Discovery sample</th>
<th>SNP selection criteria</th>
<th>SNPs n</th>
<th>ADHD v. controls</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISC</td>
<td>ISC P&lt;0.5</td>
<td>15,470</td>
<td>z-statistic</td>
<td></td>
</tr>
<tr>
<td>ISC</td>
<td>SNPs in PGC SZ and ISC, ISC P&lt;0.5</td>
<td>14,532</td>
<td>z-statistic</td>
<td></td>
</tr>
<tr>
<td>PGC SZ</td>
<td>SNPs in PGC SZ and ISC, PGC SZ P&lt;0.5</td>
<td>15,085</td>
<td>z-statistic</td>
<td></td>
</tr>
</tbody>
</table>

ADHD, attention-deficit hyperactivity disorder; SNP, single nucleotide polymorphism; ISC, International Schizophrenia Consortium; PGC SZ, Psychiatric GWAS Consortium study of schizophrenia.

In all analyses, the ADHD cases had more risk alleles than the controls. All z-statistics are distributed with one degree of freedom and all P-values are two-tailed.
Fig. DS1 Diagram of single nucleotide polymorphism (SNP) selection for polygenic score analysis.

Single nucleotide polymorphisms are selected (in regions shaded grey) if they are associated at the following levels of significance: (A) schizophrenia v. controls \( P < 0.5 \); (B) bipolar disorder v. controls \( P < 0.5 \); (C) schizophrenia v. controls \( P < 0.5 \) and bipolar disorder v. controls \( P \geq 0.5 \); (D) schizophrenia v. controls \( P < 0.5 \) and bipolar disorder v. controls \( P < 0.5 \) (total region shaded). The SNPs selected in (D) are further divided according to whether the alleles associated with schizophrenia and bipolar disorder were (1) the same (light grey), or (2) different (dark grey). The diagram is designed to enable visual interpretation of the SNP selection. In reality, the cell sizes vary. Note that not every SNP is available for analysis in each of the three samples: attention-deficit hyperactivity disorder, schizophrenia and bipolar disorder.
Fig. DS2 Results from polygenic score analysis of attention-deficit hyperactivity disorder (ADHD) v. controls, using a range of $P$-value inclusion thresholds.

Those findings that were significant in Table 1 are presented using different significance thresholds, namely 0.1, 0.2, 0.3, 0.4 and 0.5. Note that for analyses that involve the joint distribution of schizophrenia (SZ) and bipolar disorder (BD) data, the same threshold is applied to both the schizophrenia and bipolar disorder data. Consistent with the findings of the International Schizophrenia Consortium, $P<0.5$ gives most evidence for discrimination of ADHD cases from controls. The horizontal grey line indicates a $P$-value of 0.05 when comparing ADHD v. controls.
Relationship between sample used in current analysis and that in analysis by Psychiatric Genomics Collaboration Cross Disorders Group

Large-scale, collaborative analyses of psychiatric GWAS data are being undertaken under the auspices of the Psychiatric Genomics Consortium (PGC; previously known as the Psychiatric GWAS Consortium), to which we refer within the main text of this manuscript. This includes analyses across phenotypes, which are being conducted by the Cross Disorders Group (CDG) of PGC, to which we refer within the main text of this manuscript. The PGC CDG analyses are not yet published.

With the exception of 196 attention-deficit hyperactivity (ADHD) cases, our ADHD and control samples were not included in the PGC sample and, so, the data in the current analysis are essentially independent (i.e. PGC is not analysing the same data).

Our ADHD sample reported in the current manuscript is of UK/Irish origin and ascertained and assessed using a consistent approach (i.e. clinically and genetically relatively homogeneous). The PGC CDG ADHD sample is a meta-analysis of various data sets collected by differing groups in differing countries, some of which have very different clinical populations of patients with ADHD from UK/Ireland. Thus, the PGC sample has the potential for greater clinical and genetic heterogeneity.

Further, we note that the PGC CDG analyses of the ADHD sample comprise many 'pseudo controls' constructed from parent–offspring trio data. It is known that estimates of heritability from case v. pseudo control analyses tend to underestimate the truth, and this is also likely to influence estimates of genetic overlap with other traits. Our ADHD sample comprises unrelated cases and controls, whereas the PGC ADHD sample is largely family-based, so our sample is more likely to have power to show genetic overlap with schizophrenia and bipolar disorder.

Additional reference

Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia

Marian L. Hamshere, Evangelia Stergiakouli, Kate Langley, Joanna Martin, Peter Holmans, Lindsey Kent, Michael J. Owen, Michael Gill, Anita Thapar, Mick O'Donovan and Nick Craddock


Access the most recent version at DOI: 10.1192/bjp.bp.112.117432

Supplementary Material

Supplementary material can be found at:
http://bjp.rcpsych.org/content/suppl/2013/05/20/bjp.bp.112.117432.DC1

References

This article cites 24 articles, 3 of which you can access for free at:
http://bjp.rcpsych.org/content/203/2/107#BIBL

Reprints/permissions

To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;203/2/107

Downloaded from
http://bjp.rcpsych.org/ on June 27, 2017
Published by The Royal College of Psychiatrists